These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10230895)

  • 21. Prevalence of factor XII (Hageman factor) deficiency among 426 patients with coronary heart disease awaiting cardiac surgery.
    Halbmayer WM; Haushofer A; Radek J; Schön R; Deutsch M; Fischer M
    Coron Artery Dis; 1994 May; 5(5):451-4. PubMed ID: 7921377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations.
    te Velthuis H; Baufreton C; Jansen PG; Thijs CM; Hack CE; Sturk A; Wildevuur CR; Loisance DY
    J Thorac Cardiovasc Surg; 1997 Jul; 114(1):117-22. PubMed ID: 9240301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma.
    Gallimore MJ; Friberger P
    Thromb Res; 1982 Feb; 25(3):293-8. PubMed ID: 6917564
    [No Abstract]   [Full Text] [Related]  

  • 24. A novel chromogenic peptide for prekallikrein/kallikrein determination.
    Huang WY; Wan X; Zhang S
    Clin Lab; 2009; 55(3-4):106-13. PubMed ID: 19462932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of cardiopulmonary bypass on glucose homeostasis after coronary artery bypass surgery.
    Anderson RE; Brismar K; Barr G; Ivert T
    Eur J Cardiothorac Surg; 2005 Sep; 28(3):425-30. PubMed ID: 16054822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on components of the plasma kallikrein system as a risk factor in diabetics undergoing cardiopulmonary bypass.
    Heller W; Gallimore MJ; Hoffmeister HE
    Agents Actions Suppl; 1992; 38 ( Pt 3)():311-6. PubMed ID: 1281380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
    Hellstern P; Bach J; Simon M; Saggau W
    J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromogenic peptide substrate assays for determining components of the plasma kallikrein system.
    Gallimore MJ
    Scand J Clin Lab Invest Suppl; 1985; 178():127-32. PubMed ID: 3867113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Determination of factor XII and plasma prekallikrein with chromozym PK].
    Stürzebecher J; Klessen C; Markwardt F
    Z Med Lab Diagn; 1982 Oct; 23(5):306-11. PubMed ID: 6924817
    [No Abstract]   [Full Text] [Related]  

  • 30. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contact factor deficiencies and cardiopulmonary bypass surgery: detection of the defect and monitoring of heparin.
    van Veen JJ; Laidlaw S; Swanevelder J; Harvey N; Watson C; Kitchen S; Makris M
    Eur J Haematol; 2009 Mar; 82(3):208-12. PubMed ID: 19077049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromogenic peptide substrate assays and their clinical applications.
    Gallimore MJ; Friberger P
    Blood Rev; 1991 Jun; 5(2):117-27. PubMed ID: 1912757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assay of factor XII in human plasma using prekallikrein or the chromogenic peptide S-2222 as substrates--significance of the functional state of plasma kallikrein.
    Hoem NO; Johannesen S; Briseid K
    Thromb Res; 1989 May; 54(3):197-205. PubMed ID: 2787541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma.
    Friberger P; Gallimore MJ
    Adv Exp Med Biol; 1986; 198 Pt B():543-8. PubMed ID: 3643742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A simple and accurate microplate assay for the determination of factor VIII activity.
    Carlebjörk G; Oswaldsson U; Rosén S
    Thromb Res; 1987 Jul; 47(1):5-14. PubMed ID: 3116712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage.
    Citarella F; Wuillemin WA; Lubbers YT; Hack CE
    Br J Haematol; 1997 Oct; 99(1):197-205. PubMed ID: 9359524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between kallikrein release and factor XII in normal persons and carriers of the Hageman trait.
    Torres M; Ercoreca L; Lucia JF; Giralt M; Raichs A
    Thromb Haemost; 1979 Dec; 42(4):1286-8. PubMed ID: 261563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritoneal lavage efficiently eliminates protease-alpha-2-macroglobulin complexes and components of the contact system from the peritoneal cavity in patients with severe acute pancreatitis.
    Aasen AO; Ruud TE; Roeise O; Bouma BN; Stadaas JO
    Eur Surg Res; 1989; 21(1):1-10. PubMed ID: 2469582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor XII and other hemostatic protein abnormalities in nephrotic syndrome patients.
    Thompson AR
    Thromb Haemost; 1982 Aug; 48(1):27-32. PubMed ID: 6813992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Thrombomodulin as endothelial cell marker in heart surgery patients].
    Böhrer H; Böttiger BW; Haussmann R; Nawroth PP; Motsch J; Martin E
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1995 Nov; 30(7):417-9. PubMed ID: 8562716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.